References
- Frattarelli JL, Hill MJ, McWilliams GD, et al. A luteal estradiol protocol for expected poor-responders improves embryo number and quality. Fertil Steril 2008; 89:1118–22.
- Ulug U, Ben-Shlomo I, Turan E, et al. Conception rates following assisted reproduction in poor responder patients: a retrospective study in 300 consecutive cycles. Reprod Biomed Online 2003; 6:439–43.
- Burger HG. Androgen production in women. Fertil Steril 2002; 77(Suppl 4): S3–S5.
- Barad D, Gleicher N. Effect of dehydroepiandrosterone on oocyte and embryo yields, embryo grade and cell number in IVF. Hum Reprod 2006; 21:2845–9.
- Barad D, Brill H, Gleicher N. Update on the use of dehydroepiandrosterone supplementation among women with diminished ovarian function. J Assist Reprod Genet 2007; 24:629–34.
- Barad DH, Gleicher N. Increased oocyte production after treatment with dehydroepiandrosterone. Fertil Steril 2005; 84:756.
- Wiser A, Gonen O, Ghetler Y, et al. Addition of dehydroepiandrosterone (DHEA) for poor-responder patients before and during IVF treatment improves the pregnancy rate: a randomized prospective study. Hum Reprod 2010; 25:2496–500.
- Yeung TW, Chai J, Li RH, et al. A randomized, controlled, pilot trial on the effect of dehydroepiandrosterone on ovarian response markers, ovarian response, and in vitro fertilization outcomes in poor responders. Fertil Steril 2014; 102:108–15 e101.
- Hassa H, Aydin Y, Ozatik O, et al. Effects of dehydroepiandrosterone (DHEA) on follicular dynamics in a diminished ovarian reserve in vivo model. Syst Biol Reprod Med 2015; 61:117–21.
- Narkwichean A, Jayaprakasan K, Maalouf WE, et al. Effects of dehydroepiandrosterone on in vivo ovine follicular development. Hum Reprod 2014; 29:146–54.
- Miyamoto K, Sato EF, Kasahara E, et al. Effect of oxidative stress during repeated ovulation on the structure and functions of the ovary, oocytes, and their mitochondria. Free Radic Biol Med 2010; 49:674–81.
- Morgan S, Lopes F, Gourley C, et al. Cisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatin. PLoS One 2013; 8:e70117.
- Comish PB, Drumond AL, Kinnell HL, et al. Fetal cyclophosphamide exposure induces testicular cancer and reduced spermatogenesis and ovarian follicle numbers in mice. PLoS One 2014; 9:e93311.
- Abercrombie M. Estimation of nuclear population from microtome sections. Anat Rec 1946; 94:239–47.
- Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: mechanisms and clinical consequences. Endocr Rev 2009; 30:465–93.
- Sudo N, Shimizu T, Kawashima C, et al. Insulin-like growth factor-I (IGF-I) system during follicle development in the bovine ovary: relationship among IGF-I, type 1 IGF receptor (IGFR-1) and pregnancy-associated plasma protein-A (PAPP-A). Mol Cell Endocrinol 2007; 264:197–203.
- Lenie S, Smitz J. Functional AR signaling is evident in an in vitro mouse follicle culture bioassay that encompasses most stages of folliculogenesis. Biol Reprod 2009; 80:685–95.
- Nheu L, Nazareth L, Xu GY, et al. Physiological effects of androgens on human vascular endothelial and smooth muscle cells in culture. Steroids 2011; 76:1590–6.
- Sen A, Hammes SR. Granulosa cell-specific androgen receptors are critical regulators of ovarian development and function. Mol Endocrinol 2010; 24:1393–403.
- Nielsen ME, Rasmussen IA, Kristensen SG, et al. In human granulosa cells from small antral follicles, androgen receptor mRNA and androgen levels in follicular fluid correlate with FSH receptor mRNA. Mol Hum Reprod 2011; 17:63–70.